BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

BTIG analyst Mark Massaro has maintained a 'Buy' rating on Adaptive Biotechnologies (NASDAQ: ADPT) and raised the price target from $25 to $34. This adjustment reflects increased confidence in the company's performance and future prospects.